BrightFocus Foundation launches two national public service announcements encouraging eye exams to save sight from macular ...

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...

The use of anticoagulants or antiplatelets was linked to a higher risk of intraocular hemorrhage requiring vitrectomy in ...

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial ...

A new study published in the Journal of American Medical Association found that patients with exudative age-related macular ...

An analysis of pivotal phase 3 trials shows supplements to arrest age-related macular degeneration have no effect on ...

Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) ...

Discover which lifestyle moves, drops and other strategies give your eyes relief from screens, allergens, and life in general ...